Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT06594744 | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC(P-HCC-CVL) | recruiting | Phase 4 | 120 | Taipei Veterans General Hospital, TaiwanOTHER_GOV |
| 1 |
| Feb 13, 2025 |
| clinicaltrials |
| NCT06640166 | Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.(ECLYPse) | recruiting | Phase 2 | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06821958 | Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF) | recruiting | N/A | 36 | Charite University, Berlin, GermanyOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05520788 | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing(CCGLC-006) | recruiting | — | 200 | Tongji HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05920863 | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors | recruiting | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05984511 | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | recruiting | N/A | 234 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05596630 | Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC | recruiting | N/A | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06542796 | Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma | recruiting | N/A | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06813508 | Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH(BOMASH) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06333561 | HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06806579 | Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma(ARTE) | recruiting | — | 1,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06387342 | Namodenoson Treatment of Advanced Pancreatic Cancer | recruiting | Phase 2 | 20 | Can-Fite BioPharmaINDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06789679 | Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer | recruiting | Phase 2 | 128 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06492395 | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | recruiting | Phase 3 | 178 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06798376 | Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer | recruiting | — | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06707233 | Y-90 SIRT for Unresectable HCC Larger Than 7cm | recruiting | Phase 2 | 33 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06788353 | Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma | recruiting | — | 500 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06334965 | Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort(OPERANDI-HCC) | recruiting | N/A | 180 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06777017 | Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?(ELASTORFA) | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06622031 | TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT | recruiting | N/A | 42 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06767579 | Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation | recruiting | — | 350 | Yonsei UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04615143 | Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC(TALENT) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06766643 | Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06762782 | Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery | recruiting | Phase 2 | 276 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04803994 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | recruiting | Phase 3 | 434 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 6 | Jan 7, 2025 | clinicaltrials |
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | recruiting | Phase 3 | 480 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | recruiting | Phase 3 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06446154 | Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06653062 | Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance(CCGLC-015) | recruiting | — | 50 | Tongji HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06748352 | Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer | recruiting | N/A | 50 | Shandong UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06689540 | Mts105 for Advanced Hepatocellular Carcinoma(MTS105 for HCC) | recruiting | Phase 1 | 14 | Shen LinOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06746194 | The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05359939 | A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma | recruiting | N/A | 50 | University of AarhusOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05871892 | 18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma | recruiting | N/A | 125 | University of AarhusOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06349980 | A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. | recruiting | Phase 2 | 117 | Shanghai Henlius BiotechINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06558227 | Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 90 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06725121 | Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant(MacroTrans) | recruiting | Phase 1 / Phase 2 | 48 | University Health Network, TorontoOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05937295 | FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition(FusionVAC22) | recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05185739 | Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)(PRIMER-1) | recruiting | Phase 2 | 60 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06609850 | The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma | recruiting | N/A | 116 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06609863 | dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma | recruiting | N/A | 27 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06609876 | Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC | recruiting | N/A | 108 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06644430 | Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma | recruiting | — | 470 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06711211 | Spanish Registry of Digestive Tumours RETUD(RETUD) | recruiting | — | 20,000 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05475613 | Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation | recruiting | Phase 2 | 59 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2025source: clinicaltrials